Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $474,433 | 52 | 98.7% |
| Travel and Lodging | $5,949 | 3 | 1.2% |
| Food and Beverage | $540.81 | 9 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $471,115 | 56 | $0 (2022) |
| Boehringer Ingelheim International GmbH | $6,203 | 4 | $0 (2018) |
| Celgene Corporation | $3,583 | 3 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $21.87 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $21.87 | 1 | AstraZeneca Pharmaceuticals LP ($21.87) |
| 2022 | $110,000 | 12 | Vertex Pharmaceuticals Incorporated ($110,000) |
| 2021 | $137,500 | 15 | VERTEX PHARMACEUTICALS INCORPORATED ($137,500) |
| 2020 | $122,611 | 14 | Vertex Pharmaceuticals Incorporated ($122,611) |
| 2019 | $100,967 | 13 | Vertex Pharmaceuticals Incorporated ($100,967) |
| 2018 | $6,203 | 4 | Boehringer Ingelheim International GmbH ($6,203) |
| 2017 | $3,620 | 5 | Celgene Corporation ($3,583) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/27/2023 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Respiratory | ||||||
| 12/07/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 11/09/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 10/26/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 10/12/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 10/12/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 08/17/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 08/17/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 07/06/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 04/27/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 03/30/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 03/09/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 02/02/2022 | Vertex Pharmaceuticals Incorporated | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 12/21/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 11/22/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 10/27/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 09/29/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 09/15/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 07/28/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 06/29/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 06/23/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 05/26/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 04/28/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 03/24/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
| 02/24/2021 | VERTEX PHARMACEUTICALS INCORPORATED | — | Consulting Fee | Cash or cash equivalent | $9,166.66 | General |
About David Schwartz, M.D.(MPH)
David Schwartz, M.D.(MPH) is a Pulmonary Disease healthcare provider based in Aurora, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790869675.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Schwartz, M.D.(MPH) has received a total of $480,923 in payments from pharmaceutical and medical device companies, with $21.87 received in 2023. These payments were reported across 64 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($474,433).
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Pulmonary Disease
- Location Aurora, CO
- Active Since 10/25/2006
- Last Updated 02/25/2019
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1790869675
Products in Payments
- FASENRA (Biological) $21.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Aurora
Fernando Holguin, Md, MD
Pulmonary Disease — Payments: $139,522
David Badesch, Md, MD
Pulmonary Disease — Payments: $96,525
Dr. Joyce Lee, M.d, M.D
Pulmonary Disease — Payments: $76,433
Richard Albert, Md, MD
Pulmonary Disease — Payments: $73,600
Robert Winn, Md, MD
Pulmonary Disease — Payments: $56,886
Marvin Schwarz, Md, MD
Pulmonary Disease — Payments: $38,795